Physician profile
Aimin Ouyang
NPI 1962928986
$1,133.80
in general payments reported to CMS, 2019-2025
15 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $84.29 · 2023: $251 · 2024: $324 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $269.21 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbvie INC. | $147.33 | 2022-2024 | |
| Gilead Sciences, INC. | $125.00 | 2025 | |
| Exact Sciences Corporation | $118.80 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $85.91 | 2024 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $81.46 | 2023-2025 | Evenity, Prolia |
| Phadia US INC. | $59.42 | 2023-2024 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $56.46 | 2025 | Zoryve |
| Amarin Pharma, INC. | $41.26 | 2021 | |
| Pfizer INC. | $40.97 | 2021-2023 | |
| Hologic Sales and Service, LLC | $37.69 | 2023-2025 | Aptima |
| Esperion Therapeutics, INC. | $21.47 | 2021 | |
| Novo Nordisk INC | $18.17 | 2023 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.42 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.23 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimin Ouyang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.